Kawasaki Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Kawasaki disease markets are expected to exhibit a CAGR of 5.33% during 2024-2034.
The Kawasaki disease market has been comprehensively analyzed in IMARC's new report titled "Kawasaki Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Kawasaki disease refers to a rare but potentially serious childhood illness characterized by swelling of blood vessels throughout the body. This disorder primarily affects children under the age of five. The condition presents a constellation of symptoms, including a high fever persisting for at least five days, redness and swelling of the hands and feet, conjunctivitis (red eyes), a rash, and swollen lymph nodes in the neck. Additionally, children suffering from the ailment may experience irritability, a sore throat, and peeling of the skin on the fingers and toes. The diagnosis of Kawasaki disease involves a thorough evaluation of clinical symptoms and medical history, as there are no certain laboratory tests that can definitively confirm the disease. Physicians often rely on a set of diagnostic criteria that take into account the duration and nature of the fever as well as the presence of various other associated indications. Blood workups are commonly used to assess the inflammation causing the underlying condition.
The increasing incidences of abnormal immune responses triggered by an infectious agent or several other environmental factors like temperature, humidity, or changes in viral activity are primarily driving the Kawasaki disease market. In addition to this, the inflating utilization of effective therapeutic interventions, such as intravenous immunoglobulin (IVIG), aspirin, corticosteroids, etc., for the management of illness and mitigation of potential complications is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, encompassing fever-reducing measures and fluid replacement, owing to their role in alleviating symptoms and bolstering the overall recovery process in patients, is further propelling the market growth. Apart from this, the rising usage of echocardiography as a pivotal diagnostic tool to assess coronary artery involvement and cardiac function is acting as another significant growth-inducing factor. Additionally, the emerging popularity of plasmapheresis in severe cases, aimed at removing harmful antibodies from the bloodstream and reducing organ damage in individuals suffering from the ailment, is also augmenting the market growth. Furthermore, the escalating application of advanced therapeutic avenues, such as monoclonal antibodies and immunomodulatory agents, since they address the underlying immune dysregulation associated with the illness, is expected to drive the Kawasaki disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Kawasaki disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Kawasaki disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Kawasaki disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Kawasaki disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Kawasaki disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Kawasaki disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Kawasaki disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Kawasaki disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Kawasaki disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Kawasaki disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kawasaki disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kawasaki disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Kawasaki disease across the seven major markets?
What is the size of the Kawasaki disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Kawasaki disease?
What will be the growth rate of patients across the seven major markets?
Kawasaki Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Kawasaki disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Kawasaki disease market?
What are the key regulatory events related to the Kawasaki disease market?
What is the structure of clinical trial landscape by status related to the Kawasaki disease market?
What is the structure of clinical trial landscape by phase related to the Kawasaki disease market?
What is the structure of clinical trial landscape by route of administration related to the Kawasaki disease market?
The Kawasaki disease market has been comprehensively analyzed in IMARC's new report titled "Kawasaki Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Kawasaki disease refers to a rare but potentially serious childhood illness characterized by swelling of blood vessels throughout the body. This disorder primarily affects children under the age of five. The condition presents a constellation of symptoms, including a high fever persisting for at least five days, redness and swelling of the hands and feet, conjunctivitis (red eyes), a rash, and swollen lymph nodes in the neck. Additionally, children suffering from the ailment may experience irritability, a sore throat, and peeling of the skin on the fingers and toes. The diagnosis of Kawasaki disease involves a thorough evaluation of clinical symptoms and medical history, as there are no certain laboratory tests that can definitively confirm the disease. Physicians often rely on a set of diagnostic criteria that take into account the duration and nature of the fever as well as the presence of various other associated indications. Blood workups are commonly used to assess the inflammation causing the underlying condition.
The increasing incidences of abnormal immune responses triggered by an infectious agent or several other environmental factors like temperature, humidity, or changes in viral activity are primarily driving the Kawasaki disease market. In addition to this, the inflating utilization of effective therapeutic interventions, such as intravenous immunoglobulin (IVIG), aspirin, corticosteroids, etc., for the management of illness and mitigation of potential complications is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, encompassing fever-reducing measures and fluid replacement, owing to their role in alleviating symptoms and bolstering the overall recovery process in patients, is further propelling the market growth. Apart from this, the rising usage of echocardiography as a pivotal diagnostic tool to assess coronary artery involvement and cardiac function is acting as another significant growth-inducing factor. Additionally, the emerging popularity of plasmapheresis in severe cases, aimed at removing harmful antibodies from the bloodstream and reducing organ damage in individuals suffering from the ailment, is also augmenting the market growth. Furthermore, the escalating application of advanced therapeutic avenues, such as monoclonal antibodies and immunomodulatory agents, since they address the underlying immune dysregulation associated with the illness, is expected to drive the Kawasaki disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Kawasaki disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Kawasaki disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Kawasaki disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Kawasaki disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Kawasaki disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Kawasaki disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Kawasaki disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Kawasaki disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Kawasaki disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Kawasaki disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kawasaki disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kawasaki disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Kawasaki disease across the seven major markets?
What is the size of the Kawasaki disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Kawasaki disease?
What will be the growth rate of patients across the seven major markets?
Kawasaki Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Kawasaki disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Kawasaki disease market?
What are the key regulatory events related to the Kawasaki disease market?
What is the structure of clinical trial landscape by status related to the Kawasaki disease market?
What is the structure of clinical trial landscape by phase related to the Kawasaki disease market?
What is the structure of clinical trial landscape by route of administration related to the Kawasaki disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 KAWASAKI DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 KAWASAKI DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 KAWASAKI DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 KAWASAKI DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 KAWASAKI DISEASE - UNMET NEEDS
10 KAWASAKI DISEASE - KEY ENDPOINTS OF TREATMENT
11 KAWASAKI DISEASE - MARKETED PRODUCTS
11.1 List of Kawasaki Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Gammagard S/D (Immune globulin) - Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 KAWASAKI DISEASE - PIPELINE DRUGS
12.1 List of Kawasaki Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Etanercept - Amgen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. KAWASAKI DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. KAWASAKI DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 KAWASAKI DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Kawasaki Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Kawasaki Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Kawasaki Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Kawasaki Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Kawasaki Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Kawasaki Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Kawasaki Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Kawasaki Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Kawasaki Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Kawasaki Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Kawasaki Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Kawasaki Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Kawasaki Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Kawasaki Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Kawasaki Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Kawasaki Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Kawasaki Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Kawasaki Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Kawasaki Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Kawasaki Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Kawasaki Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Kawasaki Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Kawasaki Disease - Access and Reimbursement Overview
16 KAWASAKI DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 KAWASAKI DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 KAWASAKI DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 KAWASAKI DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 KAWASAKI DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 KAWASAKI DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 KAWASAKI DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 KAWASAKI DISEASE - UNMET NEEDS
10 KAWASAKI DISEASE - KEY ENDPOINTS OF TREATMENT
11 KAWASAKI DISEASE - MARKETED PRODUCTS
11.1 List of Kawasaki Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Gammagard S/D (Immune globulin) - Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 KAWASAKI DISEASE - PIPELINE DRUGS
12.1 List of Kawasaki Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Etanercept - Amgen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. KAWASAKI DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. KAWASAKI DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 KAWASAKI DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Kawasaki Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Kawasaki Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Kawasaki Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Kawasaki Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Kawasaki Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Kawasaki Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Kawasaki Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Kawasaki Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Kawasaki Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Kawasaki Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Kawasaki Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Kawasaki Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Kawasaki Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Kawasaki Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Kawasaki Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Kawasaki Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Kawasaki Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Kawasaki Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Kawasaki Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Kawasaki Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Kawasaki Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Kawasaki Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Kawasaki Disease - Access and Reimbursement Overview
16 KAWASAKI DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 KAWASAKI DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 KAWASAKI DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
